A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

It isn’t entirely clear why the efficacy ... least two years. Pfizer executives, meanwhile, pledged to increase their shot’s market share during a January investor call. Moderna has said ...

according to Pfizer. Administering a third dose restores protective efficacy back up to 95% or more, it said. Meanwhile, Moderna also reported new data with its mRNA-1273 jab – which won't be ...

The company will compete in a market where GSK and Pfizer already have a presence. Earlier this month, Moderna released data ... to compare the safety and efficacy of its RSV shot with others ...

Moderna and Pfizer have both said that updated versions ... led to concerns that the current generation of shots may lack efficacy. It's encouraging, then, that Moderna's mRNA-1273.715 vaccine ...

The FDA instead reviewed data that Pfizer and Moderna had collected from clinical studies of the safety and efficacy of earlier iterations of the shot, which had been targeted at the original Omicron ...

Most experts had hoped for 70% efficacy or higher ... of the leading vaccines require two shots. Pfizer's doses are given three weeks apart, while Moderna and AstraZeneca's are administered ...

#TeamPfizer and #TeamModerna are two of the captions often found next to selfies of proud newly vaccinated people on social media. And both groups do have a reason to celebrate as the two mRNA ...

Moderna is down 80% from its 52-week high as ... An opportunity for an early demonstration of efficacy in the phase 3 trial of MRNA's CMV vaccine has passed, but a final analysis can still arrive ...

8 at 1:30 p.m. Pfizer enrolled approximately 44,000 people ... who received two shots of the vaccine, a strong signal of efficacy. Of all those participants who became sick with covid, 10 became ...